Presentations from EuHEA 2018

OHE staff recently attended the European Health Economics Association (EuHEA) 2018 conference. In this blog post, we share a selection of our presentations.

Establishing a Reasonable Price for an Orphan Drug from Office of Health Economics

R&D, Competition and Diffusion of Innovation in EU: The Case of Direct Acting Antivirals (DAAs) for Hepatitis C from Office of Health Economics

Key factors driving access and uptake of hepatitis C treatments in Europe. Results from experts interviews from Office of Health Economics

The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public’s Preferences from Office of Health Economics

Do EQ-5D-3L and EQ-5D-5L Capture the Same Changes in Quality of Life Over Time? A Longitudinal Study of Cancer Patients from Office of Health Economics

Anchoring latent scale values for the EQ-5D-Y at 0 = dead from Office of Health Economics

Economics of Innovation
Presentations

News & Insights

Latest Research & Publications

Understanding the Full Value of Long-Acting Therapies: less is more?

An Analysis of NICE’s Optimised Decisions from 2015 to 2024

Analysing Global Immunisation Expenditure

The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region

Challenges and Solutions for Budget Impact Analysis of Gene Therapies

The Importance of Diversity of Supply in Rare Diseases Markets

2023 OHE Annual Report to the Charity Commission

Employer Costs from Respiratory Infections

All Publications

Presentations from EuHEA 2018

Related News

How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.

Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?

Funding Challenges in the Malaysian Health Care System

OHE at HESG Winter 2020

Share on Mastodon